Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Inovas | Pharma | 56.5% | 100th pct | 110 |
| Krokus Pharma | Pharma | 34.1% | 83rd pct | 110 |
| Biopolusi | Pharma | 29.2% | 74th pct | 110 |
| Neoparmi | Pharma | -2.0% | 12th pct | 110 |
| Bioparmi | Pharma | -8.3% | 5th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Line item | Neoparmi | Bioparmi | Biopolusi | Inovas | Krokus Pharma |
|---|---|---|---|---|---|
| Total Current Assets | 5,533 | 251 | 14,600 | 3,456 | 3,253 |
| Total Non-Current Assets | 2,436 | 18,847 | 58 | 2,811 | 63 |
| TOTAL ASSETS | 7,969 | 19,098 | 14,658 | 6,266 | 3,316 |
| Total Current Liabilities | 2,894 | 888 | 1,767 | 650 | 802 |
| Total Non-Current Liabilities | 0 | 0 | 1,162 | 104 | 0 |
| TOTAL LIABILITIES | 2,894 | 888 | 2,929 | 754 | 802 |
| Total Equity | 5,075 | 18,209 | 11,729 | 5,512 | 2,514 |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 |
| Total Debt | 0 | 0 | 1,162 | 742 | 0 |
| Cash & Equivalents | 264 | 1,264 | 3 | 8 | 63 |
| Net Debt | -264 | -1,264 | 1,159 | 734 | -63 |